The purpose of this study is to evaluate the safety and effectiveness of the drugs sunitinib and cediranib in patients with metastatic alveolar soft part sarcoma (ASPS) which cannot be surgically removed. Patients will be randomly assigned to receive one drug or the other, but not both.
Sunitinib is approved for treating kidney cancer and gastrointestinal stroma tumor, but its use in ASPS is considered investigational. Cediranib is an investigational drug. Both drugs work by inhibiting the development of the blood vessels that tumors need to grow and spread. They are pills that are taken orally (by mouth).